SAP, Mouse, pAb
The polyclonal antibody recognizes serum amyloid P (SAP). Serum amyloid P component (SAP) belongs to a highly conserved superfamily of calcium-dependent ligand binding and lectin (carbohydrate binding) proteins. Due to the pentameric structure these proteins are also called pentraxins. SAP is 25kDa in size. C-reactive protein (CRP) and SAP are well-charactarized short pentraxins, which are produced in the liver in response to inflammatory mediators. Pentraxin 3 (PTX3) is the prototypic long pentraxin. Both SAP and CRP are evolutionary conserved in all vertebrates and found in distant invertebrates such as the horseshoe crab (Limulus polyphemus). They share 51% residue sequence identity and 66% homology.
SAP is highly resistant to proteolysis, especially when it forms complexes with calcium-dependent ligands. SAP avidly binds to macromolecular ligands, such as nucleosomal DNA, glycosaminoglycans and amyloid fibrils. When aggregated it can bind C1q and activate the classical complement pathway.
Human SAP is not an acute phase reactant following acute stimuli, this in contrast to mouse SAP and human CRP. In mouse, SAP levels increase significantly 24 hours after challenge with lipopolysaccharide.
SAP is a normal plasma constituent that is present in cerebrospinal fluid (CSF), in the pathognomonic lesions of Alzheimer’s disease (AD), cerebrovascular and intracerebral Aβ amyloid plaques and neurofibrillary tangles. This is a result of its binding to amyloid fibrils and to paired helical filaments, respectively. The protein itself may also be directly neurocytotoxic. SAP contributes significantly to the pathogenesis of amyloidosis. The mechanism of its participation is not yet known and importantly may differ between species.
Calculate your ELISA data easily
With the ELISA calculator you can easily calculate ELISA data. Assayfit Pro helps to perform curve fitting. The calculator generates advanced reports, fit graph, fit parameters and goodness of fit are shown.
Latest Hycult Biotech news
- New Human Complement Pathway AssaysWe are very proud of our newly developed human classical and alternative complement pathway assays. They are produced in response to a growing demand for quantitative investigation of complement inhibitors or regulators at lower sample dilutions. This development aims to address the issue of false negative results, enabling more accurate and reliable analysis of complement… Read more: New Human Complement Pathway Assays
- Navigating the pitfalls in complement analysisOur colleague Erik Toonen shared his experience on how to analyze complement at the Complement-based Drug Development Summit in Boston in September 11-13th, 2023. He showed valuable insights on analyzing complements. For accurate complement analysis, it is important that not only the correct technique is used but also that pre-analytical sample handling is performed in… Read more: Navigating the pitfalls in complement analysis
- NEW Human C3d ELISAWe are happy to introduce our new ELISA (cat.# HK3017) designed to detect human C3d. What sets this assay apart is its utilization of a distinctive neo-epitope capture antibody that selectively targets a specific C3d region of the alpha chain, which is not available in other C3 variants. This way it specifically distinguishes C3d from native C3… Read more: NEW Human C3d ELISA